SCHEMBL29466705

SCHEMBL29466705

CC(C)C[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)[C@@H](C)O

nearest known ligand 0.47

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 12/20 0.47
BACE2 Q9Y5Z0 3/20 0.47
ENPEP Q07075 6/20 0.44
MME P08473 2/20 0.44
CTSD P07339 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30788029 0.96 BACE1 (0.48) BACE1BACE2ENPEPMMECTSD
SCHEMBL29502178 0.93 MME (0.47) BACE1BACE2ENPEPMME
SCHEMBL29350002 0.93 MME (0.54) BACE1BACE2MMECTSD
SCHEMBL29539640 0.92 ENPEP (0.49) ENPEP
SCHEMBL30876809 0.91 BACE1 (0.52) BACE1BACE2ENPEPMMECTSD
SCHEMBL31319509 0.91 OPRM1 (0.46) BACE1BACE2MMECTSD
SCHEMBL30463290 0.90 BACE1 (0.48) BACE1BACE2ENPEPMMECTSD
SCHEMBL30930193 0.88 MME (0.47) BACE1BACE2MMECTSD
SCHEMBL29432625 0.88 BACE1 (0.52) BACE1BACE2ENPEPCTSD
SCHEMBL29350942 0.88 MME (0.51) BACE1BACE2ENPEPMME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099508-A1 METHOD FOR PRODUCING A TRYPSIN-LIKE PROTEASE IN BACILLUS KERRY GROUP SERVICES INTERNATIONAL LTD (IE) 2026-05-15 WO claimed
EP-4741416-A1 METHOD FOR PRODUCING A TRYPSIN-LIKE PROTEASE IN BACILLUS Kerry Group Services International Ltd (IE) 2026-05-13 EP claimed
EP-4698219-A2 ALPHA-HEMOLYSIN COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST STAPHYLOCOCCUS AUREUS Washington University (US) 2026-02-25 EP claimed
CN-120051271-A Methods for treating infectious diseases 欣扬生医股份有限公司 2025-05-27 CN claimed
CN-119923837-A User equipment assistance information for timing management of multiple TRPs in wireless communications 苹果公司 2025-05-02 CN claimed
CN-119739940-A Carbon emission calculation method, system and equipment in power transmission and transformation engineering construction process 国网湖北省电力有限公司经济技术研究院 2025-04-01 CN claimed
EP-4522128-A1 METHOD FOR TREATING INFECTIOUS DISEASE Suntec Medical, Inc. (US) 2025-03-19 EP claimed
CN-118853721-A Acid-resistant escherichia coli engineering bacteria and preparation method and application thereof 中国科学院天津工业生物技术研究所 2024-10-29 CN claimed
WO-2024220535-A2 ALPHA-HEMOLYSIN COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST STAPHYLOCOCCUS AUREUS WASHINGTON UNIVERSITY (US) 2024-10-24 WO claimed
CN-117708961-B Integrated intelligent reconstruction method for three-dimensional space line position of existing railway 中南大学 2024-04-30 CN claimed
CN-117390855-A Target access time rapid calculation method based on satellite orbit space-time relationship model 中国电子科技集团公司第五十四研究所 2024-01-12 CN claimed
CN-117143209-A Enterococcus lipoteichoic acid synthetic protein multi-epitope antigen, preparation method and application thereof 宁波大学 2023-12-01 CN claimed
WO-2023220086-A1 METHOD FOR TREATING INFECTIOUS DISEASE SUNTEC MEDICAL, INC. (US) 2023-11-16 WO claimed
WO-2026099508-A1 METHOD FOR PRODUCING A TRYPSIN-LIKE PROTEASE IN BACILLUS KERRY GROUP SERVICES INTERNATIONAL LTD (IE) 2026-05-15 WO disclosed
EP-4741416-A1 METHOD FOR PRODUCING A TRYPSIN-LIKE PROTEASE IN BACILLUS Kerry Group Services International Ltd (IE) 2026-05-13 EP disclosed
WO-2026090614-A1 HIGH-THROUGHPUT METHODS FOR THE RAPID GENERATION OF AFFINITY REAGENTS AND USES THEREOF THE UNIVERSITY OF CHICAGO (US) 2026-04-30 WO disclosed
EP-4065732-A1 METHODS AND COMPOSITIONS FOR PROVIDING IDENTIFICATION AND/OR TRACEABILITY OF BIOLOGICAL MATERIAL Index Biosystems Inc. (CA) 2022-10-05 EP disclosed
CN-114945665-A Compositions and methods for enhancing protein production in bacillus licheniformis 丹尼斯科美国公司 2022-08-26 CN disclosed
EP-3703756-B1 USE OF STATINS IN OVERCOMING RESISTANCE TO BETA-LACTAM ANTIBIOTICS IN BACTERIAL SPECIES SYNTHETIZING ISOPRENOIDS USING THE MEVALONATE SYNTHETIC PATHWAY CONSEJO SUPERIOR INVESTIGACION (ES) 2022-04-20 EP disclosed
US-11305001-B2 Multiple antigen presenting system (MAPS)-based Staphylococcus aureus vaccine, immunogenic composition, and uses thereof THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2022-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11305001-B2 Multiple antigen presenting system (MAPS)-based Staphylococcus aureus vaccine, immunogenic composition, and uses thereof CD14, TLR8, SPAG5 BACE1 2786/4885BACE2 3062/4885ENPEP 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.